# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-of...
Oppenheimer analyst Jeff Jones maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and lowers the price target fro...
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $...
Oppenheimer analyst Jeff Jones initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announce...
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule me...
Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price t...
Piper Sandler analyst Edward Tenthoff maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price tar...